AI assistant
ABBOTT LABORATORIES — Director's Dealing 2014
Feb 25, 2014
29777_dirs_2014-02-25_e0491557-0d02-4555-9b59-7e4c50b03c56.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2014-02-21
Reporting Person: Doyle Katherine C. (Senior Vice President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-02-21 | Common shares without par value | A | 14220 | — | Acquired | 58207 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-02-21 | Option (right to buy) | $39.12 | A | 87061 | Acquired | 2024-02-20 | Common shares (87061) | Direct |
Footnotes
F1: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.
F2: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 29,021 on 2/21/2015, 29,020 on 2/21/2016, and 29,020 on 2/21/2017.